Skip to main content
Clinical Trials/NCT03283358
NCT03283358CompletedNot Applicable

Person-centered Follow up and Health Promotion Program After Revascularization for Intermittent Claudication

Karolinska Institutet3 sites in 1 country213 target enrollmentStarted: June 13, 2016Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
213
Locations
3
Primary Endpoint
Adherence to medication

Study Overview

Brief Summary

The overall aim of the study is to evaluate a nurse-led intervention (person-centered follow up and health promotion) program in comparison to standard follow up for patients treated with surgical or endovascular revascularization of Intermittent Claudication.

Detailed Description

Specific Aims:

  1. To evaluate the effect of the intervention program on patient's adherence to medication (anticoagulant agents, antiplatelet agents and lipid-lowering agents), risk modification and surgical treatment outcomes
  2. To investigate the effect of the intervention program on patient reported outcomes
  3. To investigate the effect of the intervention program on patient reported experiences
  4. To investigate the long-term effect of the intervention program on mortality, cause of death, occurrence/recurrence of cardiovascular disease up to 10 years after the surgical/endovascular treatment
  5. To compare patient-reported adherence to medication and patient data registry adherence to medication

Hypothesis: Participants in the Intervention Group have better adherence to prescribed medication and a reduced risk for 10-year predicted coronary heart disease (CHD) compared to participants in the Control Group.

Study population:

Patients with Intermittent Claudication scheduled for revascularization, through open surgery or endovascular method, in Stockholm will be screened for inclusion. After informed consent, the participants will be randomized to either Intervention Group or Control Group. Those participants who couldn't receive revascularization after giving consent will be withdrawn from the study and counted as drop outs. Power analysis has showed a required sample size of 186 participants to detect a statistically significant increase in adherence to medication from 50% to 70% (power 0.80, significance value 0.05, two-sided). Expecting 10% drop-out we plan to recruit 210 participants.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult patients who is scheduled for revascularization, through open and/or endovascular surgery for IC diagnosed according to Diagnosis Related Group (DRG) with I70.2 or I739B

Exclusion Criteria

  • Patients not treated through surgery or revascularization
  • Patients diagnosed with dementia
  • Patients discharge to a nursery home,
  • Patients not accountable for administrating their own medications
  • Patients with a survival expectancy less than one year

Outcomes

Primary Outcomes

Adherence to medication

Time Frame: One year after surgical or endovascular treatment for Intermittent Claudication

Adherence to medication (anticoagulant agents, antiplatelet agents and lipid-lowering agents) according to the Swedish Prescribed Drug Registry (PDR). dispensed anticoagulant agents, antiplatelet agents (ATC-register B01A) and lipid-lowering agents (ATC-register C10). Those participants who have fetched both medications for the second refill after treatment will be considered adherent.

Secondary Outcomes

  • Risk for 10-year predicted coronary heart disease (CHD)(One year after surgical or endovascular treatment for Intermittent Claudication)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Anneli Linné

MD, PhD

Karolinska Institutet

Study Sites (3)

Loading locations...

Similar Trials